Literature DB >> 22790860

Adrenocortical tumors: improving the practice of the Weiss system through virtual microscopy: a National Program of the French Network INCa-COMETE.

Frédérique Tissier1, Sébastien Aubert, Emmanuelle Leteurtre, Abir Al Ghuzlan, Martine Patey, Myriam Decaussin, Laurent Doucet, Françoise Gobet, Catherine Hoang, Catherine Mazerolles, Geneviève Monges, Karine Renaudin, Nathalie Sturm, Hélène Trouette, Marie-Cécile Vacher-Lavenu, Vivian Viallon, Eric Baudin, Xavier Bertagna, Joël Coste, Rossella Libe.   

Abstract

The Weiss score is the reference method to distinguish between a benign and a malignant adrenocortical tumor (ACT). A program was initiated to improve the reproducibility of the pathologic diagnosis of ACTs in France through the National INCa-COMETE Network. Twelve pathologists from all Reference Centers of the Network analyzed 50 selected ACTs using a web-based virtual microscopy approach in a blind design, allowing to determine the intraobserver and interobserver reproducibilities of the Weiss system. All ACTs were read twice in random order before and after a coaching meeting organized to harmonize and improve analyses and create an online tutorial. The validity of the virtual approach was first established by comparing the 2 consensuses (virtual and microscopic) obtained for each tumor by 3 pathologists who performed the 2 approaches in a blinded manner. For the "dichotomized Weiss score" (separating malignant ≥3 from benign ≤2 tumors) interobserver reproducibility was "substantial" at the first "virtual" reading (κ = 0.70) and increased at the second "virtual" reading (κ = 0.75). In parallel, 7 of the 9 items of the Weiss system showed improvement. The diagnostic accuracy of the observers as a group, using the modal group score approach, showed an improved sensitivity from 86% to 95% for the diagnosis of malignant ACTs. We show the validity of the virtual microscopy approach and that the program improved the practice of the Weiss system reading and therefore the diagnosis of ACT. This tool can now be extended for other research and/or routine purposes in this rare cancer.

Entities:  

Mesh:

Year:  2012        PMID: 22790860     DOI: 10.1097/PAS.0b013e31825a6308

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  14 in total

1.  Management of adrenocortical carcinoma: a consensus statement of the Italian Society of Endocrinology (SIE).

Authors:  A Stigliano; I Chiodini; R Giordano; A Faggiano; L Canu; S Della Casa; P Loli; M Luconi; F Mantero; M Terzolo
Journal:  J Endocrinol Invest       Date:  2015-07-14       Impact factor: 4.256

2.  P53/Rb inhibition induces metastatic adrenocortical carcinomas in a preclinical transgenic model.

Authors:  M Batisse-Lignier; I Sahut-Barnola; F Tissier; T Dumontet; M Mathieu; C Drelon; J-C Pointud; C Damon-Soubeyrand; G Marceau; J-L Kemeny; J Bertherat; I Tauveron; P Val; A Martinez; A-M Lefrançois-Martinez
Journal:  Oncogene       Date:  2017-04-03       Impact factor: 9.867

3.  Pathology of the adrenal cortex: a reappraisal of the past 25 years focusing on adrenal cortical tumors.

Authors:  Mauro Papotti; Eleonora Duregon; Marco Volante; Anne Marie McNicol
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

Review 4.  The 'omics' of adrenocortical tumours for personalized medicine.

Authors:  Guillaume Assié; Anne Jouinot; Jérôme Bertherat
Journal:  Nat Rev Endocrinol       Date:  2014-02-04       Impact factor: 43.330

5.  Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors.

Authors:  Delphine Vezzosi; Christine Do Cao; Ségolène Hescot; Jérôme Bertherat; Magali Haissaguerre; Vanina Bongard; Delphine Drui; Christelle De La Fouchardière; Frédéric Illouz; Françoise Borson-Chazot; Bodale Djobo; Amandine Berdelou; Antoine Tabarin; Martin Schlumberger; Claire Briet; Philippe Caron; Sophie Leboulleux; Rossella Libe; Eric Baudin
Journal:  Horm Cancer       Date:  2017-10-25       Impact factor: 3.869

6.  Transcriptome in paraffin samples for the diagnosis and prognosis of adrenocortical carcinoma.

Authors:  Anne Jouinot; Juliane Lippert; Mathilde Sibony; Florian Violon; Lindsay Jeanpierre; Daniel De Murat; Roberta Armignacco; Amandine Septier; Karine Perlemoine; Franck Letourneur; Brigitte Izac; Bruno Ragazzon; Karen Leroy; Eric Pasmant; Marie-Odile North; Sébastien Gaujoux; Bertrand Dousset; Lionel Groussin; Rossella Libe; Benoit Terris; Martin Fassnacht; Cristina L Ronchi; Jérôme Bertherat; Guillaume Assie
Journal:  Eur J Endocrinol       Date:  2022-04-21       Impact factor: 6.558

7.  Molecular Profiling of Refractory Adrenocortical Cancers and Predictive Biomarkers to Therapy.

Authors:  Sherri Z Millis; Samuel Ejadi; Michael J Demeure
Journal:  Biomark Cancer       Date:  2015-12-17

Review 8.  Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment.

Authors:  Rossella Libé
Journal:  Front Cell Dev Biol       Date:  2015-07-03

Review 9.  Adrenocortical Carcinoma: Updates of Clinical and Pathological Features after Renewed World Health Organisation Classification and Pathology Staging.

Authors:  Alfred King-Yin Lam
Journal:  Biomedicines       Date:  2021-02-10

10.  Histological scores and tumor size on stage II in adrenocortical carcinomas.

Authors:  Rui Caetano Oliveira; Maria João Martins; Carolina Moreno; Rui Almeida; João Carvalho; Paulo Teixeira; Miguel Teixeira; Edgar Tavares Silva; Isabel Paiva; Arnaldo Figueiredo; Maria Augusta Cipriano
Journal:  Rare Tumors       Date:  2021-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.